Show simple item record

dc.contributor.authorGurcan, T
dc.contributor.authorKiziltas, S
dc.contributor.authorSiva, A
dc.contributor.authorImeryuz, N
dc.contributor.authorUlusoy, NB
dc.contributor.authorSaip, S
dc.contributor.authorKalayci, C
dc.contributor.authorDumankar, A
dc.date.accessioned2021-03-03T08:16:26Z
dc.date.available2021-03-03T08:16:26Z
dc.date.issued1998
dc.identifier.citationKiziltas S., Imeryuz N., Gurcan T., Siva A., Saip S., Dumankar A., Kalayci C., Ulusoy N., "Corticosteroid therapy augments gastroduodenal permeability to sucrose", AMERICAN JOURNAL OF GASTROENTEROLOGY, cilt.93, sa.12, ss.2420-2425, 1998
dc.identifier.issn0002-9270
dc.identifier.otherav_16a7a094-ef8a-4f4a-b3cd-fdb460a47c3a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/20560
dc.identifier.urihttps://doi.org/10.1111/j.1572-0241.1998.00697.x
dc.description.abstractObjective: The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Methods: Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5 +/- 0.1 g; duration, similar to 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7 +/- 0.5 g; duration, similar to 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography, Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. Results: The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy, The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p < 0.01), Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4 +/- 1.5 g exhibited mucosal lesions, whereas patients who received 3.3 +/- 1.8 g did not (p = 0.06). The posttherapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Conclusions: Corticosteroid therapy augments gastroduodenal permeability and high doses are associated,vith macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions. (C) 1998 by Am. Coll. of Gastroenterology.
dc.language.isoeng
dc.subjectGastroenteroloji-(Hepatoloji)
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.titleCorticosteroid therapy augments gastroduodenal permeability to sucrose
dc.typeMakale
dc.relation.journalAMERICAN JOURNAL OF GASTROENTEROLOGY
dc.contributor.department, ,
dc.identifier.volume93
dc.identifier.issue12
dc.identifier.startpage2420
dc.identifier.endpage2425
dc.contributor.firstauthorID121830


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record